Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

(2020) Shuhong Shen et al.   JAMA Oncology

Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

(2020) Ardine M. J. Reedijk et al.   LEUKEMIA

Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements

(2019) Ilaria Tanasi et al.   BLOOD

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

(2019) Gunnar Cario et al.   HAEMATOLOGICA

Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group

(2018) Kathryn G. Roberts et al.   BLOOD

IKZF1plus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

(2018) Martin Stanulla et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622

(2018) William B. Slayton et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up of Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor

(2018) Andrea Biondi et al.   HAEMATOLOGICA

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial

(2018) Andrea Biondi et al.   Lancet Haematology

Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group

(2017) Naomi Winick et al.   JOURNAL OF CLINICAL ONCOLOGY

EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications

(2016) C. Schwab et al.   BLOOD

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

(2016) Rob Pieters et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan

(2016) T Imamura et al.   Blood Cancer Journal

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

(2016) Judith M. Boer et al.   Oncotarget

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine

(2015) S. P. Hunger et al.   BLOOD

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

(2014) K R Schultz et al.   LEUKEMIA

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

(2013) A. van der Veer et al.   BLOOD

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL

(2013) A. van der Veer et al.   BLOOD

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

(2013) E. Lengline et al.   HAEMATOLOGICA

Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia

(2013) Brent W. Weston et al.   JOURNAL OF CLINICAL ONCOLOGY

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

(2013) H Lilljebjörn et al.   LEUKEMIA

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

(2012) Kathryn G. Roberts et al.   CANCER CELL

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

(2012) Andrea Biondi et al.   LANCET ONCOLOGY

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

(2009) Monique L Den Boer et al.   LANCET ONCOLOGY

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE